Study directory

Mental health studies with practical context.

Compare studies and check their requirements with the research team.

Back to overview

10648studies shown

Showing 8,713-8,724 of 10,648

Behavioral study icon

CompletedNCT00364910

Safety and Efficacy of Cognitive Behavior Therapy for People With Post-traumatic Stress and Cardiovascular Illness

This summary needs review. Please check the official study record and contact the research team for details.

In United States

PTSDBehavioralOver 21 Years

Countries: United States
Sponsor: Icahn School of Medicine at Mount Sinai
Condition: PTSD

Drug study icon

CompletedNCT00419445

Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder

This summary needs review. Please check the official study record and contact the research team for details.

In United States

ADHDDrugFrom 18 Years to 55 Years

Countries: United States
Sponsor: CoMentis
Condition: ADHD

Drug study icon

CompletedNCT05071430

Safety and Efficacy of HB-1 for Panic Disorder

This summary needs review. Please check the official study record and contact the research team for details.

In United States

AnxietyDrugFrom 18 Years to 60 Years

Countries: United States
Sponsor: HB BioTech, LLC
Condition: Anxiety

Drug study icon

CompletedNCT00374920

Safety and Efficacy of MEM 1003 Versus Placebo for people with Bipolarity type I

This summary needs review. Please check the official study record and contact the research team for details.

In United States

BipolarityDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Memory Pharmaceuticals
Condition: Bipolarity

Drug study icon

CompletedNCT04044664

Safety and Efficacy of NYX-783 in Subjects With PTSD

This summary needs review. Please check the official study record and contact the research team for details.

In United States

PTSDDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Aptinyx
Condition: PTSD

Drug study icon

CompletedNCT00447564

Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence

This summary needs review. Please check the official study record and contact the research team for details.

In United States

AddictionDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Titan Pharmaceuticals
Condition: Addiction

Drug study icon

CompletedNCT00852202

Safety and Efficacy of RGH-188 (Cariprazine) in Depression in bipolarity

This summary needs review. Please check the official study record and contact the research team for details.

In United States

Bipolarity, DepressionDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Forest Laboratories
Condition: Bipolarity, Depression

Drug study icon

CompletedNCT00202605

Safety and Efficacy of SPD465 in Adults With ADHD

This summary needs review. Please check the official study record and contact the research team for details.

In United States

ADHDDrugFrom 18 Years to 55 Years

Countries: United States
Sponsor: Shire
Condition: ADHD

Drug study icon

WithdrawnNCT01274221

Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

This summary needs review. Please check the official study record and contact the research team for details.

In United States

ADHDDrugFrom 13 Years to 17 Years

Countries: United States
Sponsor: Shire
Condition: ADHD

Drug study icon

CompletedNCT01101022

Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

This summary needs review. Please check the official study record and contact the research team for details.

In United States

ADHDDrugFrom 18 Years to 55 Years

Countries: United States
Sponsor: Shire
Condition: ADHD

Drug study icon

CompletedNCT00063297

Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In United States

SchizophreniaDrugFrom 18 Years to 60 Years

Countries: United States
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Condition: Schizophrenia

Drug study icon

CompletedNCT00485875

Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD

This summary needs review. Please check the official study record and contact the research team for details.

In United States

ADHDDrugFrom 6 Years to 17 Years

Countries: United States
Sponsor: Eli Lilly and Company
Condition: ADHD

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.